Confronto
CJC-1295 vs. Follistatin (FST)
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Crescita
Crescita
N. CAS
nessun dato
122956-17-2
Peso molecolare
3647.3 g/mol
35000 g/mol
Emivita
144 h
nessun dato
Sequenza
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACGlykoprotein, ~315 Aminosäuren in der zirkulierenden Hauptform (Sequenz isoformabhängig, kein einheitliches kurzes Peptid)Meccanismo d'azione
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Follistatin (FST)
Follistatin binds with high affinity to activin and to myostatin (GDF-8), as well as related TGF-β ligands such as GDF-11 and some BMPs, preventing their binding to the activin type-II receptors. Myostatin is a negative regulator of skeletal muscle mass; by sequestering myostatin, its growth-inhibiting signalling is removed (de-repression). Because follistatin additionally neutralises activin, it acts on several muscle-inhibiting pathways at once — in animal models this produced greater muscle gain than knocking out myostatin alone. Several isoforms exist (including FST-288 and FST-315) that differ in tissue binding via heparan sulfate. The FST344 variant used in gene therapy was chosen to reduce binding to off-target structures.
Base di evidenze
Evidenza più alta
Studio sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
3
1
Effetti registrati
3
4
Contraddizioni aperte
1
1
Eventi avversi documentati
3
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between CJC-1295 and Follistatin (FST)?
- CJC-1295 is classified as "Crescita", while Follistatin (FST) is classified as "Crescita". CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. Follistatin (FST): Follistatin is an endogenous glycosylated binding protein (~35 kDa, considerably larger than typical peptides) that binds and neutralises members of the TGF-β superfamily, including activin and myostatin (GDF-8). In animal models, raising follistatin de-represses muscle growth. Clinically it has been studied mainly via AAV gene therapy (FS344) in muscular dystrophies. Follistatin is not an approved drug; human efficacy and safety data are limited and stem mostly from early gene-therapy trials and preclinical research. A 'follistatin-344' product is sold on the grey market, the identity and purity of which cannot be verified without analytics. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CJC-1295 or Follistatin (FST)?
- The highest available evidence level is "Studio sull'uomo" for CJC-1295 and "Studio sull'uomo" for Follistatin (FST). A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CJC-1295 and Follistatin (FST) in Germany and the United States?
- Germania: CJC-1295 — Non approvato, Follistatin (FST) — Non approvato. Stati Uniti: CJC-1295 — Solo ricerca, Follistatin (FST) — Non approvato. These are factual summaries with source and review date on the individual pages.